As one of the key immune cells in TME of HER2-positive breast cancer and TNBC, tumor-infiltrating lymphocytes (TILs), primarily consisting of CD8+ cytotoxic T cells, CD4+ helper T cells, regulatory T cells (Tregs) and NK cells, etc., indicates a better prognosis (64–67). The gene discussed is CD8A; the disease is breast carcinoma.